MEDCURA Establishes Elite Advisory Board for Cutting-Edge Spinal Surgery Innovations

COLLEGE PARK, Md., Jan. 16, 2025 – Medcura, Inc. has formed a new Spinal Surgery Advisory Board. This group brings together nine leading spine surgeons known for their expertise in clinical trials and medical device design. Their goal is to help Medcura advance its product, LifeGel™ Absorbable Hemostatic Gel, through the necessary clinical trials and regulatory approvals.

“We’re thrilled to have such talented spine surgeons on board,” said Chief Medical Officer Kenneth Renkens, MD. “Their knowledge will be crucial as we work to bring this innovative hemostatic agent to market. With their guidance, we aim to meet the needs of spine surgeons and enhance patient care.”

Dr. Renkens leads this advisory board. He is a well-respected neurosurgeon and co-founder of the Indiana Spine Group, with over 30 years in surgical innovation. He has participated in multiple hemostatic studies, contributing significantly to clinical advancements in the field.

The advisory board is composed of these notable experts:

• Adedayo Ashana, MD, Minimally Invasive Spine Specialist, OrthoNC, Raleigh, North Carolina
• Barrett Boody, MD, Orthopedic Spine Surgeon, Indiana Spine Group, and Assistant Professor at Indiana University Health
• Bryan Cunningham, PhD, Director of Scientific Orthopaedic Research, MedStar Union Memorial Hospital
• Peter Grossi, MD, Chief Physician Executive, Duke Health
• Serena Hu, MD, Chief of Spine Surgery, Stanford University
• Jun S. Kim, MD, Assistant Professor of Orthopedics, Mount Sinai
• Paul McAfee, MD, MBA, Chief of Spinal Research, Union Memorial Hospital
• Kornelis Poelstra, MD, PhD, Spine Surgeon, Allegiant Spine Institute, Las Vegas
• Nicholas Theodore, MD, Director, Neurosurgical Spine Center, Johns Hopkins Medicine
• Alexander Vaccaro, MD, PhD, MBA, Chairman of Orthopaedic Surgery, Thomas Jefferson University Hospital

LifeGel™ is noteworthy for being the first surgical hemostatic agent to receive the FDA Breakthrough Device Designation. It aims to provide safer options for controlling surgical bleeding. Traditional hemostatic agents can sometimes lead to complications, such as swelling that might cause neurological issues. LifeGel’s unique no-swell feature helps address these risks while delivering additional benefits, such as cost-effectiveness and freshness at the time of use. It has even won the 2024/2025 Best Technology in Spine Award.

Medcura itself is a pioneering medical device company focused on creating versatile hemostatic products. By utilizing safe, effective ingredients and innovative technology, Medcura aims to offer lower-cost solutions for managing bleeding in various medical contexts. For example, their products have been recognized by the FDA for their potential in both spine surgeries and other medical procedures.

For more information about Medcura’s developments, visit their official [website](https://www.medcurainc.com).

Media Contact
Shannon Severino
Email: Shannon.Severino@powers-co.com
Phone: (412) 608-2393

Source link

Indiana Spine Group, spine surgeons, Spinal Surgery, hemostatic agent, Advisory Board, Orthopedic Spine Surgeon, Georgetown University School of Medicine, Kenneth Renkens, Spine Surgery, surgical fellowship, commercialization, Indiana University Health